Fresenius Kabi And Formycon Ally On Stelara Rival
German Firms Strike Global Licensing Agreement For FYB202 Ustekinumab Biosimilar
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.
You may also be interested in...
A third settlement has been struck allowing a Stelara biosimilar to hit the US market in 2025, with partners Fresenius and Formycon agreeing terms with Johnson & Johnson that offer a launch date slightly later than previous settlers.
Speaking during the firm’s Q2 results call, J&J management has indicated that it does not expect biosimilar competition to Stelara to hit the market until at least 2025.
Celltrion has filed its CT-P43 proposed ustekinumab biosimilar rival to Stelara with the US Food and Drug Administration and Health Canada.